Six patients with ALCL, ALK positive had a favorable prognosis compared with patients with other PTCL subtypes, with only one case had disease progression and died within 2 years, and the remaining 5 cases had been free of disease progression until the last follow-up. This evidence concerns the gene ALK and mature T-cell and NK-cell non-Hodgkin lymphoma.